Keywords: Almirall, Invida, Menarini, Aclidinium, Australia, New Zealand, COPD
Almirall out-licenses aclidinium to Invida for Australia and New Zealand
Article | 12 October 2012
Leading Spanish drugmaker Almirall (ALM: MC) has granted Singapore-based Invida, a member of the Italian family-owned Menarini Group, commercial rights ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
